-
Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series HIV Med. (IF 3.0) Pub Date : 2024-03-17 Yanyun Dou, Ruichao Lu, Lingsong Su, Ke Lan, Zhihao Meng, Shanfang Qin, Liling Huang, Wei Huang, Yuanlong Xu, Yu Lv, Yuhong Wen, Shuanglai Lan, Yong Zuo, Yong Zhang
Dolutegravir + lamivudine (DTG + 3TC) is a first-line regimen for people with HIV. However, there are still concerns about its efficacy in people with tuberculosis (TB)/HIV due to the lack of available evidence and drug–drug interaction with rifampicin.
-
Early HIV viral suppression associated with subsequent 12‐month treatment success among people living with HIV in South Africa HIV Med. (IF 3.0) Pub Date : 2024-03-16 Lauren R. Violette, Katherine K. Thomas, Jienchi Dorward, Justice Quame‐Amaglo, Nigel Garrett, Paul K. Drain
BackgroundWe analyzed the STREAM (Simplifying HIV TREAtment and Monitoring) study to determine risk factors associated with HIV viraemia and poor retention 18 months after initiation of antiretroviral therapy (ART).MethodsThe STREAM study was an open‐label randomized controlled trial in Durban, South Africa, that enrolled 390 people living with HIV presenting for their first HIV viral load measurement
-
The effect of HIV and mpox co‐infection on clinical outcomes: Systematic review and meta‐analysis HIV Med. (IF 3.0) Pub Date : 2024-03-06 Amira Mohamed Taha, Amr Elrosasy, Abdelrahman Mohamed Mahmoud, Sara Adel Abdelkader Saed, Wesam Abd El‐Tawab Moawad, Esraa Hamouda, Dang Nguyen, Van Phu Tran, Hoang Tran Pham, Sanjit Sah, Joshuan J. Barboza, Ranjit Sah
IntroductionCo‐infection with HIV and mpox is a significant issue for public health because of the potential combined impact on clinical outcomes. However, the existing literature lacks a comprehensive synthesis of the available evidence. The purpose of this meta‐analysis is to provide insight into the impact of HIV and mpox co‐infection on clinical outcomes.MethodsWe systematically searched major
-
-
SARS-CoV-2 testing, positivity, and factors associated with COVID-19 among people with HIV across Europe in the multinational EuroSIDA cohort HIV Med. (IF 3.0) Pub Date : 2024-03-03 O. Fursa, W. Bannister, B. Neesgaard, D. Podlekareva, J. Kowalska, T. Benfield, J. Gerstoft, J. Reekie, L. D. Rasmussen, I. Aho, G. Guaraldi, T. Staub, J. M. Miro, J. M. Laporte, D. Elbirt, T. Trofimova, D. Sedlacek, R. Matulionyte, C. Oprea, E. Bernasconi, V. Hadžiosmanović, A. Mocroft, L. Peters
Although people with HIV might be at risk of severe outcomes from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; coronavirus 2019 [COVID-19]), regional and temporal differences in SARS-CoV-2 testing in people with HIV across Europe have not been previously described.
-
Immunological alterations with GLP‐1 agonists in people living with HIV HIV Med. (IF 3.0) Pub Date : 2024-03-04 Sebastian Noe, Anna Ivanova, Celia Johnsson‐Oldenbüttel, Guido Schäfer, Knud Schewe, Christian Hoffmann
-
Experiences with health care services and HIV testing after sexual assault in cisgender gay, bisexual and other men who have sex with men and transgender people HIV Med. (IF 3.0) Pub Date : 2024-03-04 Romain Palich, Alison J. Rodger, Emily Jay Nicholls, Talen Wright, Phil Samba, Isaac Yen‐Hao Chu, Fiona M. Burns, Peter Weatherburn, Roy Trevelion, Leanne McCabe, T. Charles Witzel
ObjectivesThis qualitative sub‐study aimed to explore how cisgender gay, bisexual, and other men who have sex with men (cis‐GBMSM) and transgender people who reported non‐consensual sex (NCS) accessed health care services, what barriers they faced, and how this experience influenced subsequent HIV testing.MethodsSELPHI is an online randomized controlled trial evaluating both acceptability and efficiency
-
Framingham risk score based vascular outcomes in acute versus chronic HIV cohorts after 6 years of ART HIV Med. (IF 3.0) Pub Date : 2024-02-21 Kathryn Brown Holroyd, Win Min Han, Tanakorn Apornpong, Lydie Trautmann, Sivaporn Gatechompol, Akarin Hiransuthikul, Sasiwimol Ubolyam, Carlo Sacdalan, Somchai Sriplienchan, Ratchapong Kanaprach, Stephen Kerr, Anchalee Avihingsanon, Serena Spudich, Phillip Chan
Immune dysregulation persists in people with HIV (PWH) on antiretroviral therapy (ART) and may lead to accelerated vascular ageing and cardiovascular disease (CVD). While delayed time to initiation of ART has been linked to worse cardiovascular outcomes, the effect of ART initiation during acute infection on these outcomes is not well understood.
-
Asymptomatic monkeypox infection and highly sexually active MSM population HIV Med. (IF 3.0) Pub Date : 2024-02-21 Amnuay Kleebayoon, Viroj Wiwanitkit
-
Sex differences in the effectiveness and tolerability of dolutegravir plus rilpivirine as a switch strategy in people living with HIV HIV Med. (IF 3.0) Pub Date : 2024-02-21 Luis Ramos‐Ruperto, Maria del Mar Arcos‐Rueda, Rosa de Miguel‐Buckley, Carmen Busca‐Arenzana, Rafael Mican, Rocío Montejano, Ana Delgado‐Hierro, María Luisa Montes, María Eulalia Valencia, Lucía Serrano, José Ramon Arribas, Juan González, Jose Ignacio Bernardino, Luz Martín‐Carbonero
IntroductionDolutegravir + rilpivirine (DTG + RPV) is an effective antiretroviral therapy regimen approved in clinical guidelines as a switch therapy for virologically suppressed people with HIV. Our study aimed to compare the effectiveness and tolerability of DTG + RPV in women and men in real‐world clinical practice.MethodsThis was a retrospective analysis of treatment‐experienced people with HIV
-
Cytomegalovirus infection among people living with HIV in Sweden: Case profiles, treatment strategies and patient outcomes at Karolinska University Hospital 2010–2020 HIV Med. (IF 3.0) Pub Date : 2024-02-13 Xinling Xu, Emmi Andersson, Afsar Rahbar, Cecilia Söderberg-Nauclér, Piotr Nowak
In countries with access to early antiretroviral treatment (ART), opportunistic infections caused by cytomegalovirus (CMV) in people living with HIV (PLWH) are becoming increasingly rare. As potential complications are severe, it is critical to remain aware of this important diagnosis. However, clinical characteristics and prognosis of CMV infection in PLWH in the era of modern ART have not been well
-
CD4+ T-cell recovery in HIV/hepatitis C co-infected patients following successful hepatitis C treatment HIV Med. (IF 3.0) Pub Date : 2024-01-25 Patrick Ryscavage, Siham Hussien, Hyunuk Seung, Lauren Hynicka
Hepatitis C virus (HCV)/HIV co-infection has been identified as a risk for impaired CD4+ T-cell recovery, possibly mediated by HCV-induced liver fibrosis and/or immune activation. As HCV direct-acting antivirals (DAAs) may partially reverse liver fibrosis and immune activation, sustained HCV virological response (SVR) may lead to improved CD4 recovery. We explored the effect of HCV DAA-induced SVR
-
Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations HIV Med. (IF 3.0) Pub Date : 2024-01-23 Roberto Rossotti, Federico D'Amico, Nicholas Brian Bana, Alice Nava, Leonardo Francesco Rezzonico, Alessandro Raimondi, Diana Fanti, Leonardo Gerolamo Chianura, Maria Cristina Moioli, Chiara Vismara, Massimo Puoti
The availability of doravirine (DOR) allowed clinicians to prescribe a dolutegravir (DTG)-based two-drug regimen (2DR) in individuals not eligible to receive lamivudine (3TC) or rilpivirine (RPV). The aims of this study were to describe the durability of DTG + DOR compared with DTG/3TC and DTG/RPV and the rate of virological failure and target not-detected maintenance over time.
-
Potentially inappropriate prescriptions and potential prescription omissions in older people living with HIV HIV Med. (IF 3.0) Pub Date : 2024-01-23 Jorge Fernández-Fradejas, Eva Delgado-Silveira, Elena González-Burgos, Ana María Álvarez-Díaz, Manuel Vélez-Díaz-Pallarés
This study aimed to determine the prevalence of potentially inappropriate prescriptions (PIPs) and potential prescription omissions (PPOs) in a Spanish cohort of people living with HIV (PLWH) aged ≥65 years and to identify risk factors for the presence of PIPs and PPOs.
-
The changing landscape of both causes and locations of death in a regional HIV population 2010–2021 HIV Med. (IF 3.0) Pub Date : 2024-01-19 Hartmut B. Krentz, Raynell Lang, Jacqueline McMillian, Meagan Ody, M. John Gill
Although HIV-related deaths among people with HIV have dramatically decreased, deaths from other medical conditions and non-medical events have increased. The location of death among people with HIV remains underreported.
-
High prevalence of impaired glucose metabolism among children and adolescents living with HIV in Ghana HIV Med. (IF 3.0) Pub Date : 2024-01-19 Ruth Ayanful-Torgby, Veronika Shabanova, Akosua A. Essuman, Emmanuel Boafo, Frank Aboagye, Yusuf Al-Mahroof, Jones Amponsah, John K. A. Tetteh, Linda E. Amoah, Elijah Paintsil
Antiretroviral therapy (ART)-associated metabolic abnormalities, including impairment of glucose metabolism, are prevalent in adults living with HIV. However, the prevalence and pathogenesis of impaired glucose metabolism in children and adolescents living with HIV, particularly in sub-Saharan Africa, are not well characterized. We investigated the prevalence of impaired glucose metabolism among children
-
Screening and prevention of HPV-related anogenital cancers in women living with HIV in Europe: Results from a systematic review HIV Med. (IF 3.0) Pub Date : 2024-01-18 Dagny Krankowska, Maria Mazzitelli, Hazal Albayrak Ucak, Eva Orviz, Hanife Nur Karakoc, Harriet Mortimer, Karoline Aebi-Popp, Yvonne Gilleece
Women living with HIV (WLWH) are at increased risk of human papillomavirus (HPV)-related cancers. Throughout Europe, there is great heterogeneity among guidelines for screening programmes, access to HPV testing and HPV vaccination. The aim of this systematic review is to summarize available data on screening and prevention measures for HPV-related anogenital cancers in WLWH across the WHO European
-
Correction to ‘Abstracts of the 19th European AIDS Conference (#EACS2023), October 18–21, 2023, Warsaw, Poland’ HIV Med. (IF 3.0) Pub Date : 2024-01-15
(2023), EACS Abstracts. HIV Med, 24: 3–675. https://doi.org/10.1111/hiv.13572 (2023), Late breaker abstracts. HIV Med, 24: 676–708. https://doi.org/10.1111/hiv.13573 (2023), Clinical Case Abstracts. HIV Med, 24: 709–788. https://doi.org/10.1111/hiv.13574 The EACS abstracts listed below were inadvertently included, but were initially rejected from the programme by the scientific committee. These have
-
Perspectives of people with HIV and HIV clinicians on characteristics of antiretroviral treatment and HIV-related symptoms HIV Med. (IF 3.0) Pub Date : 2024-01-12 M. José Galindo Puerto, J. Puig, J. A. Pérez-Molina, M. J. Fuster-Ruiz de Apodaca
We aimed to assess HIV symptoms from the perspective of both patients and HIV specialists and the impact of discontinuing antiretroviral treatment (ART) on symptomology. We gathered opinions from HIV specialists and people living with HIV about ideal ART parameters and treatment satisfaction.
-
Clinical epidemiology of COVID-19 in people of black ethnicity living with HIV in the UK HIV Med. (IF 3.0) Pub Date : 2024-01-11 Zoe Ottaway, Lucy Campbell, Laura R. Cechin, Nisha Patel, Julie Fox, Fiona Burns, Lisa Hamzah, Stephen Kegg, Melanie Rosenvinge, Sarah Schoeman, David Price, Rachael Jones, Amanda Clarke, Irfaan Mann, Andrew Ustianowski, Denis Onyango, Shema Tariq, Robert F. Miller, Frank A. Post
To describe the clinical epidemiology of COVID-19 in people of black ethnicity living with HIV in the UK.
-
Impact of social determinants of health on time to antiretroviral therapy initiation and HIV viral undetectability for migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite B/F/TAF: ‘The ASAP study’ HIV Med. (IF 3.0) Pub Date : 2024-01-11 Anish K. Arora, Serge Vicente, Kim Engler, David Lessard, Edmundo Huerta, Joel Ishak, Jean-Pierre Routy, Marina Klein, Nadine Kronfli, Joseph Cox, Benoit Lemire, Alexandra de Pokomandy, Lina Del Balso, Giada Sebastiani, Isabelle Vedel, Amélie Quesnel-Vallée, , Bertrand Lebouché
Multidisciplinary care with free, rapid, and on-site bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) dispensation may improve health outcomes among migrants living with HIV. However, models for rapid B/F/TAF initiation are not well studied among migrants living with HIV, and an understanding of how social determinants of health (SDH) may affect HIV-related health outcomes for migrants enrolled
-
Barriers to HIV testing and possible interventions to improve access to HIV healthcare among migrants, with a focus on migrant women: Results from a European survey HIV Med. (IF 3.0) Pub Date : 2024-01-10 Dagny C. Krankowska, Panagiota Lourida, Siobhan M. Quirke, Melvina Woode Owusu, Nina Weis
According to European Centre for Disease Prevention and Control (ECDC) reports, women and migrants are more likely to have delayed HIV diagnosis (CD4 <350 cells/mm3). As a follow-up to a previously published systematic review revealing a range of barriers to HIV testing among migrant women, the aim of the present study was to identify barriers to HIV testing from the perspective of service providers
-
Factors associated with sex differences in viral non-suppression in the Swedish InfCareHIV cohort: An observational real-world study HIV Med. (IF 3.0) Pub Date : 2024-01-09 Maria Lindh, Johanna Brännström, Anton Reepalu, Veronica Svedhem, Åsa Mellgren
Women living with HIV are underrepresented in clinical trials assessing outcomes of antiretroviral treatment (ART), justifying the need for observational studies. We investigated differences in viral non-suppression between women and men in the Swedish InfCareHIV cohort and analysed results in relation to biological and socio-demographic variables and patient-reported outcome measures (PROMs).
-
The role of an artificial intelligence model in antiretroviral therapy counselling and advice for people living with HIV HIV Med. (IF 3.0) Pub Date : 2024-01-02 Matthew Chung Yi Koh, Jinghao Nicholas Ngiam, Joy Yong, Paul Anantharajah Tambyah, Sophia Archuleta
People living with HIV may find personalized access to accurate information on antiretroviral therapy (ART) challenging given the stigma and costs potentially associated with attending physical consultations. Artificial intelligence (AI) chatbots such as ChatGPT may help to lower barriers to accessing information addressing concerns around ART initiation. However, the safety and accuracy of the information
-
Nutrition counselling and clinical outcomes in HIV: A systematic review and meta-analysis HIV Med. (IF 3.0) Pub Date : 2023-12-29 Temitayo Rebecca Okusanya, Elile Monisola Okoka, Moshood Abiodun Kuyebi, Oluwafemi Temitayo Oyadiran, Temitope Kowe, Ramadhani Abdallah Noor, Moshood Olanrewaju Omotayo, Ajibola Ibraheem Abioye
People living with the HIV (PLHIV) are at an increased risk of various diseases due to a weakened immune system, particularly if they are naïve or poorly adherent to antiretroviral therapy (ART). Nutrients play a critical role in improving immune health, especially among this population. We systematically reviewed the evidence concerning the impact of nutritional counselling on the occurrence of important
-
Prevalence of, risk factors for, and target organ damage from metabolic syndrome among people living with HIV on ART: A cross-sectional analysis in Chongqing, China HIV Med. (IF 3.0) Pub Date : 2023-12-29 Min Liu, Kun He, Yushan Wu, Qing Yu, Nannan Sun, Xiaochun Teng, Xianqin Meng, Jing Yuan, Honghong Yang
The incidence of metabolic syndrome (MetS) in people living with HIV is significantly higher than in people without HIV. MetS is not only a major driver of cardiovascular disease (CVD) but is also closely related to the development of chronic kidney disease (CKD). The aim of this study was to investigate the prevalence of and risk factors for MetS and to further understand the degree of damage to target
-
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts HIV Med. (IF 3.0) Pub Date : 2023-12-26 Stefan Esser, Jason Brunetta, Alexy Inciarte, Itzchak Levy, Antonella D'Arminio Monforte, John S. Lambert, Berend van Welzen, Katsuji Teruya, Marta Boffito, Chun-Eng Liu, Ozlem Altuntas Aydın, David Thorpe, Marion Heinzkill, Andrea Marongiu, Tali Cassidy, Richard Haubrich, Lisa D'Amato, Olivier Robineau
Real-world evidence is an essential component of evidence-based medicine. The aim of the BICSTaR (BICtegravir Single Tablet Regimen) study is to assess effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in antiretroviral treatment-naïve (TN) and treatment-experienced (TE) people with HIV.
-
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96 HIV Med. (IF 3.0) Pub Date : 2023-12-26 Shinichi Oka, Vicki Holohan, Takuma Shirasaka, Jun Yong Choi, Yeon-Sook Kim, Nadine Chamay, Parul Patel, Joseph W. Polli, Susan L. Ford, Herta Crauwels, Louise Garside, Ronald D'Amico, Christine Latham, Rodica van Solingen-Ristea, Bryan Baugh, Jean van Wyk
Cabotegravir + rilpivirine (CAB + RPV) dosed monthly or every 2 months is the first complete long-acting (LA) regimen recommended by treatment guidelines for the maintenance of HIV-1 virological suppression. This post hoc analysis summarizes outcomes for Asian participants through week 96.
-
HIV and type 2 diabetes: An evolving story HIV Med. (IF 3.0) Pub Date : 2023-12-18 Harriet Daultrey, Tom Levett, Nick Oliver, Jaime Vera, Ali J Chakera
Diabetes is widely reported to be more common in people living with HIV (PLWH). Much of the data supporting this originated during the earlier HIV era. The perceived increased risk of type 2 diabetes is reflected in HIV clinical guidelines that recommend screening for diabetes in PLWH on anti-retroviral therapy (ART). However, international HIV clinical guidelines do not agree on the best marker of
-
Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects HIV Med. (IF 3.0) Pub Date : 2023-12-17 Alice Ranzani, Francesco Castelli, Antonio Di Biagio, Antonella d'Arminio Monforte, Antonio D'Avolio, Alessandro Soria, Francesca Bai, Emanuele Focà, Lucia Taramasso, Andrea Calcagno, Elena Bresciani, Antonio Torsello, Paolo Bonfanti, Giuseppe Lapadula
To investigate whether efavirenz (EFV) or 8-hydroxy-EFV (8-OH-EFV) plasma levels are associated with neurocognitive impairment and central nervous system (CNS) side effects.
-
Predictors of poor health-related quality of life among people living with HIV aged ≥60 years in the PISCIS cohort: Findings from the Vive+ project HIV Med. (IF 3.0) Pub Date : 2023-12-13 Andreu Bruguera, L. Egea-Cortés, J. Mesías-Gazmuri, J. Palacio -Vieira, C. G. Forero, C. Miranda, M. Saumoy, E. Fernández, G. Navarro, A. Orti, J. M. Miró, J. Casabona, J. Reyes-Urueña
Advancements in and accessibility to effective antiretroviral therapy has improved the life expectancy of people living with HIV, increasing the proportion of people living with HIV reaching older age (≥60 years), making this population's health-related quality of life (HRQoL) more relevant. Our aim was to identify the determinants of poor HRQoL in people living with HIV aged ≥60 years and compare
-
Areas with high HIV prevalence: A spatial analysis of nationwide claims data in Germany HIV Med. (IF 3.0) Pub Date : 2023-12-10 M. K. Akmatov, E. Hu, R. Rüsenberg, C. Kollan, D. Schmidt, C. Kohring, J. Holstiege, M. Bickel, J. Bätzing
We aimed to identify spatial clusters of high HIV prevalence in Germany.
-
Implementation of frailty screening for older people living with HIV in Brighton, UK HIV Med. (IF 3.0) Pub Date : 2023-12-07 Natalie St Clair-Sullivan, Katherine Bristowe, Inayat Khan, Matthew Maddocks, Richard Harding, Stephen Bremner, Thomas Levett, Jonathan Roberts, Zoe Adler, Deokhee Yi, Jaime H. Vera
To evaluate the implementation of frailty screening in people living with HIV (PLWH) in a large urban cohort of patients in Brighton, UK.
-
Status of HIV and comorbidities in refugees with HIV from Ukraine HIV Med. (IF 3.0) Pub Date : 2023-12-03 Gerrit Ahrenstorf, Alexandra Dopfer-Jablonka, Oana Joean, Christine Knuth, Marc Silchmueller, Thea Thiele, Felix C. Ringshausen, Hortense Slevogt, Torsten Witte, Georg M. N. Behrens
To describe the clinical characteristics of refugees with HIV from Ukraine that seek continuation of medical care in Germany.
-
Abstracts of the 19th European AIDS Conference (#EACS2023), October 18-21, 2023, Warsaw, Poland. HIV Med. (IF 3.0) Pub Date : 2023-12-01
-
HIV pre-exposure prophylaxis services, provision, and delivery in the European treatment network of HIV, hepatitis and global emerging infectious diseases (NEAT ID) HIV Med. (IF 3.0) Pub Date : 2023-12-01 Geoffroy Liegeon, Annie Duffy, Caroline Brooks, Hannah Honour, Anton Pozniak, Jean Michel Molina
We conducted a survey to evaluate HIV pre-exposure prophylaxis (PrEP) practices in a European clinical research network on HIV, hepatitis, and global infectious diseases (NEAT ID).
-
Impact of screening programme to prevent anal cancer in high-risk patients with HIV HIV Med. (IF 3.0) Pub Date : 2023-11-30 Eloïse Leclerc, Christine Jacomet, Laurent Siproudhis, Laurent Abramowitz, Bruno Pereira, Anthony Buisson
We assessed the impact of a nationwide screening programme to reduce the risk of anal cancer in a large cohort of high-risk patients with HIV.
-
Guidelines and practice of breastfeeding in women living with HIV—Results from the European INSURE survey HIV Med. (IF 3.0) Pub Date : 2023-11-29 A. Keane, F. Lyons, K. Aebi-Popp, C. Feiterna-Sperling, H. Lyall, A. Martínez Hoffart, H. Scherpbier, C. Thorne, H. Albayrak Ucak, A. Haberl
Antiretroviral therapy (ART) is integral to HIV prevention, including averting vertical transmission. The World Health Organization (WHO) recommends ART and breastfeeding for all women living with HIV for at least 12 months post-partum [1, 2]. Much of the data on HIV transmission through breastfeeding comes from low-resource settings, with a paucity of data on breastfeeding-related HIV transmission
-
Propositive follow-up: Long-term immune responses to the 4CMenB and MenACWY vaccines in people living with HIV HIV Med. (IF 3.0) Pub Date : 2023-11-28 Alberto San Francisco Ramos, Catherine Isitt, Shehnaz Athaide, Shamez N. Ladhani, Nicholas J. Andrews, Kelly Townsend-Payne, Ann Holland, Jennifer Louth, Ray Borrow, Paul T. Heath, Catherine A. Cosgrove
People living with HIV have an increased risk of meningococcal disease. The Propositive trial evaluated co-administration of two doses of a four-component recombinant protein-based MenB vaccine (4CMenB) and a quadrivalent conjugate polysaccharide MenACWY vaccine (MenACWY-CRM197) given 1 month apart in people with HIV. The follow-up trial assessed the immunogenicity of these vaccines at 1.5 and 2.5 years
-
HIV disease metrics and COVID-19 infection severity and outcomes in people living with HIV in central and eastern Europe HIV Med. (IF 3.0) Pub Date : 2023-11-28 Cristiana Oprea, Siobhan Quirke, Irina Ianache, Dominik Bursa, Sergii Antoniak, Nikolina Bogdanic, Anne I. Vassilenko, Kersti Aimla, Raimonda Matulionyte, Nino Rukhadze, Arjan Harxhi, Lukáš Fleischhans, Botond Lakatos, Dalibor Sedlacek, Gordana Dragovic, Antonija Verhaz, Nina Yancheva, Oguzhan Acet, Konstantinos Protopapas, Justyna Dominika Kowalska
To date there remains much ambiguity in the literature regarding the immunological interplay between SARS-CoV-2 and HIV and the true risk posed to coinfected individuals. There has been little conclusive data regarding the use of CD4 cell count and HIV viral load stratification as predictors of COVID-19 severity in this cohort.
-
Tackling ageism in the healthcare system: A community perspective. HIV Med. (IF 3.0) Pub Date : 2023-11-27 Nicoletta Policek,Luís Mendão
-
Effects of a hospital discharge clinic among people with HIV: Lack of early follow-up is associated with 30-day hospital readmission and decreased retention in care HIV Med. (IF 3.0) Pub Date : 2023-11-27 Lucas Hill, Courtney Thompson, Shannon Balcombe, Sonia Jain, Feng He, Maile Karris-Young, Thomas C. S. Martin, Afsana Karim, Laura Bamford, Robert Deiss
The transition between inpatient and outpatient care for hospitalized people with HIV represents an opportunity for linkage and re-engagement in care. We evaluated whether attendance at a post-hospitalization visit (‘discharge clinic’) within 1–2 weeks of discharge would reduce readmissions and improve retention in care (RIC) among people with HIV in San Diego, California, USA.
-
Comorbidity of Myasthenia gravis and Graves' disease as immune reconstitution-associated autoimmune disease in HIV infection: A case report and literature review HIV Med. (IF 3.0) Pub Date : 2023-11-22 Lianfeng Lu, Yanan Ma, Yang Cong, Baotong Zhou, Yeye Chen, Jingwen Niu, Yun He, Wei Cao, Taisheng Li
Comorbidity of Myasthenia gravis (MG) and Graves' disease (GD) in treated HIV-infected individuals has rarely been described and little study has been done on the link between HIV-related immune reconstitution and autoimmune diseases occurring post antiretroviral therapy.
-
Quality of life among people living with HIV aged 50 years and over in Australia: Identifying opportunities to support better ageing HIV Med. (IF 3.0) Pub Date : 2023-11-22 Joshua Dawe, Dean Cassano, Richard Keane, Simon Ruth, Anna Lee Wilkinson, Imogen Elsum, Jack Gunn, Graham Brown, Michael West, Jennifer Hoy, Jennifer Power, Mark Stoové
Improved life expectancy has led to an ageing population of people living with HIV in most countries. Research on ageing among people living with HIV has predominantly focused on physical and health-related quality of life rather than multidimensional quality of life. We measured quality of life among older people living with HIV in Australia and identified opportunities to guide the development and
-
Clinical significance and management of low-level HIV viremia in the era of integrase strand transfer inhibitors HIV Med. (IF 3.0) Pub Date : 2023-11-22 Jinchuan Shi, Gaoxiang Ying, Rongrong Zheng, Zhongdong Zhang
People living with HIV (PLWH) and receiving antiretroviral therapy (ART) have a goal of achieving and maintaining viral suppression; however, the existence of PLWH that show events of low-level viremia (LLV) between 50 and 1000 copies/mL and with different virological consequences have been observed. Moreover, some reports indicate that LLV status can lead to residual immune activation and inflammation
-
Ageing with HIV; a victory, a challenge and a call to action HIV Med. (IF 3.0) Pub Date : 2023-11-22 Janine M. Trevillyan, Georg Behrens
CONFLICT OF INTEREST STATEMENT JMTs institution has received honoraria for speaker responsibilities and contributions to advisory boards from ViiV, Gilead Health Sciences, and Moderna.
-
Are glucagon-like peptide 1 receptor agonists effective in decreasing body weight and body mass index in people living with diabetes and HIV? HIV Med. (IF 3.0) Pub Date : 2023-11-21 Martina Bottanelli,Laura Galli,Monica Guffanti,Antonella Castagna,Camilla Muccini
-
People with HIV and healthcare workers views on screening for cognitive impairment in people with HIV: A qualitative study HIV Med. (IF 3.0) Pub Date : 2023-11-21 Kate Alford, Shiraaz Sidat, Katherine Bristowe, Natalie St. Clair-Sullivan, Gary Parteger, Maddocks Matthew, Deokhee Yi, Richard Harding, Tom Levett, Stephen Bremner, Jaime H. Vera
People with HIV are an ageing population with an increased risk of cognitive impairment. Although cognitive impairment is dependent upon assessment, the acceptability of screening for cognitive impairment is unclear. This study aimed to explore the views of people with HIV and healthcare workers regarding routine screening for cognitive impairment.
-
Impact of steatotic liver disease and non-alcoholic steatohepatitis on cognitive impairment in people living with HIV: A cross-sectional study HIV Med. (IF 3.0) Pub Date : 2023-11-17 Win Min Han, Akarin Hiransuthikul, Kathryn B. Holroyd, Tanakorn Apornpong, Hay Mar Lwin, Sivaporn Gatechompol, Sasiwimol Ubolyam, Stephen Kerr, Anchalee Avihingsanon
The link between fatty liver diseases and cognitive impairment among people living with HIV (PLWH) remains unclear. We investigated the association of steatotic liver disease (SLD), advanced liver fibrosis and non-alcoholic steatohepatitis (NASH) with significant activity and liver fibrosis with cognitive impairment in PLWH.
-
Hepatitis delta in HIV/hepatitis B coinfection: A call for action HIV Med. (IF 3.0) Pub Date : 2023-11-15 Didem Celik, Kathrin van Bremen, Sven Breitschwerdt, Fauzi Elamouri, Tracy Swan, Christoph Boesecke, Jürgen K. Rockstroh, Patrick Ingiliz
Hepatitis D virus (HDV) infection is caused by a defective RNA virus that can only replicate in the presence of hepatitis B virus (HBV) infection. Indeed, hepatitis B surface antigen (HBsAg) serves as the viral envelope for HDV, which shares the same hepatocyte receptor [1, 2]. Overall, there are eight distinct genotypes of HDV, with genotype 1 being the most common worldwide [3, 4]. Globally, different
-
British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical investigation and management of pyrexia of unknown origin 2023 HIV Med. (IF 3.0) Pub Date : 2023-11-13 C. L. van Halsema, C. P. Eades, V. J. Johnston, R. F. Miller
1 INTRODUCTION Now that the majority of people living with HIV take combination antiretroviral therapy (ART), the spectrum of causes of pyrexia of unknown origin (PUO) has changed compared with the pre-ART era. In these guidelines, we focus on causes and evaluation of PUO among people living with HIV with CD4 counts <350 cells/mm3. Causes of PUO in people living with HIV with higher CD4 counts are
-
Immunostimulatory effects of Hsp70 fragments and Hsp27 in design of novel HIV-1 vaccine formulations HIV Med. (IF 3.0) Pub Date : 2023-11-07 Alireza Milani, Elahe Akbari, Parisa Moradi Pordanjani, Fateme Jamshidi, Shahrzad Ghayoumi, Seyed Amir Sadeghi, Azam Bolhassani
Heat shock proteins (HSPs) as an adjuvant induce antigen-specific immunity through facilitating antigen presentation and stimulating T cells. In this study, the immunostimulatory properties of two major fragments of Hsp70 (N-Hsp70(aa 1–387) with ATPase property and C-Hsp70 (aa 508–641) with peptide-binding capacity) and the full length of Hsp27 as vaccine adjuvants were evaluated to boost HIV-1 Nef
-
Variations in CD4 counts during pregnancy in women living with HIV HIV Med. (IF 3.0) Pub Date : 2023-10-25 Isabelle Boucoiran, Hélène C. F. Côté, Caroline Jodoin, Chelsea Elwood, Fatima Kakkar, Silvie Valois, Deborah M. Money, Hugo Soudeyns
Our objective was to determine the frequency at which CD4 counts drop below 200 cells/mm3 during pregnancy in women living with HIV and to identify factors associated with this.
-
High prevalence of low high-density lipoprotein cholesterol and insulin resistance among children and adolescents living with HIV in Uganda: harbinger for metabolic syndrome? HIV Med. (IF 3.0) Pub Date : 2023-10-25 Grace Kisitu, Veronika Shabanova, Fairuzi Naiga, Mary Nakagwa, Adeodata R. Kekitiinwa, Peter J. Elyanu, Elijah Paintsil
Antiretroviral therapy-associated adverse effects and comorbidities are still pervasive in people living with HIV, especially metabolic syndrome (MetS). We investigated the age-dependent prevalence of components of MetS and insulin resistance in children and adolescents living with HIV (CALWH).
-
International AIDS society conference 2023 summary HIV Med. (IF 3.0) Pub Date : 2023-10-23 Laura Waters, Yusuf Hassan Wada, Tristan J. Barber
This article summarizes key research presented at the International AIDS Society (IAS) Conference in Brisbane, held in July 2023.
-
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023 HIV Med. (IF 3.0) Pub Date : 2023-10-18 Juan Ambrosioni, Laura Levi, Jasmini Alagaratnam, Kathrin Van Bremen, Andrea Mastrangelo, Hylke Waalewijn, Jean-Michel Molina, Giovanni Guaraldi, Alan Winston, Christoph Boesecke, Paola Cinque, Alasdair Bamford, Alexandra Calmy, Catia Marzolini, Esteban Martínez, Cristiana Oprea, Steven Welch, Anna Koval, Luis Mendao, Jürgen K. Rockstroh
The European AIDS Clinical Society (EACS) guidelines were revised in 2023 for the 19th time, and all aspects of HIV care were updated.
-
Effectiveness of intensive adherence counselling in achieving an undetectable viral load among people on antiretroviral therapy with low-level viraemia in Uganda HIV Med. (IF 3.0) Pub Date : 2023-10-18 Nicholus Nanyeenya, Damalie Nakanjako, Fredrick Makumbi, Gertrude Nakigozi, Fred Nalugoda, Godfrey Kigozi, Esther Nasuuna, Simon P. S. Kibira, Susan Nabadda, Charles Kiyaga, Mutyaba Huzaifah, Noah Kiwanuka
Uganda was using a threshold of 1000 copies/mL to determine viral non-suppression for antiretroviral therapy monitoring among people living with HIV, prior to this study. It was not clear whether people living with HIV with low-level viraemia (LLV, ≥50 to <1000 copies/mL) would benefit from intensive adherence counselling (IAC). The purpose of this study was to determine the effectiveness of IAC among
-
Longitudinal changes in body fat and metabolic complications in young people with perinatally acquired HIV HIV Med. (IF 3.0) Pub Date : 2023-10-16 Sahera Dirajlal-Fargo, Denise L. Jacobson, Wendy Yu, Ayesha Mirza, Mitchell E. Geffner, Grace A. Mccomsey, Jennifer Jao
The role of body fat on metabolic complications remains poorly understood in young people living with perinatally acquired HIV (YPHIV).
-
Sero-negative HIV, a need for presumptive HIV diagnosis in adults in developing countries. HIV Med. (IF 3.0) Pub Date : 2023-10-12 Robert Ndege
-
HIV cure: Are we going to make history? HIV Med. (IF 3.0) Pub Date : 2023-10-11 Shuvasree Payra, Pramod Kumar Manjhi, Shruti Singh, Rajesh Kumar, Sunil Kumar Singh, Alok Kumar, Vikas Maharshi
At present, combination antiretroviral therapy (cART) is the mainstay for the treatment of people living with HIV/AIDS. cART can suppress the viral load to a minimal level; however, the possibility of the emergence of full-blown AIDS is always there. In the latter part of the first decade of the 21st century, an HIV-positive person received stem cell transplantation (SCT) for treatment of his haematological